Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2021 Filed Jun 4, 2021 20:03 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 285 | $208.96 | $59,553.60 |
DisclosureSEC source: 0001209191-21-038182 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,465 F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $208.96 (range $208.64 to $209.48). F3 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:09 UTC |
MCGLYNN MARGARET GDirector
|
GrantDeferred Stock Units · Derivative | 699 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037619 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Common Stock · 699 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. F1 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2020, Ms. McGlynn deferred the receipt of 699 shares of common stock and received instead 699 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 699 shares of common stock in exchange for an equal number of deferred stock units. F2 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. F2 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:09 UTC |
MCGLYNN MARGARET GDirector
|
Disposition to issuerCommon Stock | 699 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037619 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099 F1 · price: Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2020, Ms. McGlynn deferred the receipt of 699 shares of common stock and received instead 699 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 699 shares of common stock in exchange for an equal number of deferred stock units. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:06 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 311 | $210.04 | $65,322.44 |
DisclosureSEC source: 0001209191-21-037127 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,953 Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:02 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 15 | $217.13 | $3,256.95 |
DisclosureSEC source: 0001209191-21-033983 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,589 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $217.13 (range $216.86 to $217.50). Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:02 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 56 | $216.31 | $12,113.36 |
DisclosureSEC source: 0001209191-21-033983 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,604 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $216.31 (range $215.83 to $216.80). Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:02 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 8 | $215.31 | $1,722.48 |
DisclosureSEC source: 0001209191-21-033983 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,660 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.31 (range $214.83 to $215.77). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:04 UTC |
Arbuckle Stuart AEVP, Chief Comm & Ops Officer
|
SaleCommon Stock | 16 | $217.15 | $3,474.40 |
DisclosureSEC source: 0001209191-21-033984 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Comm & Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,103 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $217.15 (range $216.83 to $217.32). Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:04 UTC |
Arbuckle Stuart AEVP, Chief Comm & Ops Officer
|
SaleCommon Stock | 86 | $216.36 | $18,606.96 |
DisclosureSEC source: 0001209191-21-033984 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Comm & Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,119 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $216.36 (range $215.82 to $216.76). Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:04 UTC |
Arbuckle Stuart AEVP, Chief Comm & Ops Officer
|
SaleCommon Stock | 7 | $215.33 | $1,507.31 |
DisclosureSEC source: 0001209191-21-033984 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Comm & Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,205 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.33 (range $214.82 to $215.80). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:06 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 47 | $216.88 | $10,193.36 |
DisclosureSEC source: 0001209191-21-033986 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,253 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.95 (range $215.42 to $216.34). F4 · price: Open market sales reported on this line occurred at a weighted average price of $216.88 (range $216.43 to $217.21). Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:06 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 65 | $215.95 | $14,036.75 |
DisclosureSEC source: 0001209191-21-033986 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,300 F1 · kind: Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.95 (range $215.42 to $216.34). F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:08 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 5 | $217.27 | $1,086.35 |
DisclosureSEC source: 0001209191-21-033989 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,133 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $217.27 (range $217.05 to $217.46). Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:08 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 32 | $216.40 | $6,924.80 |
DisclosureSEC source: 0001209191-21-033989 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,138 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $216.40 (range $215.95 to $216.91). Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:08 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 8 | $215.59 | $1,724.72 |
DisclosureSEC source: 0001209191-21-033989 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,170 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.59 (range $214.94 to $215.93). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 47 | $216.88 | $10,193.36 |
DisclosureSEC source: 0001209191-21-033992 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,108 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $216.88 (range $216.44 to $217.21). Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:10 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 65 | $215.95 | $14,036.75 |
DisclosureSEC source: 0001209191-21-033992 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,155 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.95 (range $215.42 to $216.32). F3 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2021 Filed May 6, 2021 01:23 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 459 | $218.83 | $100,442.97 |
DisclosureSEC source: 0001209191-21-030522 · doc4.xml · nonDerivative · entry 3 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,108 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $218.83 (range $218.52 to $219.24). Read SEC document |
| May 03, 2021 Filed May 6, 2021 01:23 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 501 | $218.06 | $109,248.06 |
DisclosureSEC source: 0001209191-21-030522 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,567 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $218.06 (range $217.51 to $218.49). F3 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:05 UTC |
Bhatia Sangeeta N.Director
|
GrantCommon Stock | 1,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029837 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:07 UTC |
CARNEY LLOYDDirector
|
GrantCommon Stock | 1,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029842 · doc4.xml · nonDerivative · entry 1 CARNEY LLOYD · CIK 0001204424 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,401 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:08 UTC |
Garber Alan MDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,067 | $0.00 Strike: $217.20 | $0.00 |
DisclosureSEC source: 0001209191-21-029845 · doc4.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,067 Underlying: Common Stock · 6,067 shares Expires 2031-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:12 UTC |
Kearney Terrence CDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,067 | $0.00 Strike: $217.20 | $0.00 |
DisclosureSEC source: 0001209191-21-029850 · doc4.xml · derivative · entry 1 Kearney Terrence C · CIK 0001289098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,067 Underlying: Common Stock · 6,067 shares Expires 2031-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:13 UTC |
Lee YuchunDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,067 | $0.00 Strike: $217.20 | $0.00 |
DisclosureSEC source: 0001209191-21-029852 · doc4.xml · derivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,067 Underlying: Common Stock · 6,067 shares Expires 2031-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:17 UTC |
MCGLYNN MARGARET GDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,034 | $0.00 Strike: $217.20 | $0.00 |
DisclosureSEC source: 0001209191-21-029861 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,034 Underlying: Common Stock · 3,034 shares Expires 2031-04-30 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:17 UTC |
MCGLYNN MARGARET GDirector
|
GrantCommon Stock | 921 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029861 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,798 F1 · shares: Restricted stock unit award that vests on the first anniversary of the grant date. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:18 UTC |
MCKENZIE DIANADirector
|
GrantCommon Stock | 1,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029865 · doc4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:20 UTC |
SACHS BRUCE IDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,067 | $0.00 Strike: $217.20 | $0.00 |
DisclosureSEC source: 0001209191-21-029869 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,067 Underlying: Common Stock · 6,067 shares Expires 2031-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| April 30, 2021 Filed May 6, 2021 01:23 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 766 | $217.21 | $166,382.86 |
DisclosureSEC source: 0001209191-21-030522 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,068 Read SEC document |
| April 30, 2021 Filed May 6, 2021 01:26 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 547 | $217.21 | $118,813.87 |
DisclosureSEC source: 0001209191-21-030524 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,679 Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 20:03 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,884 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-21-028984 · doc4.xml · derivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,884 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 20:03 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 200 | $217.69 | $43,538.00 |
DisclosureSEC source: 0001209191-21-028984 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,133 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $217.69 (range $217.60 to $217.78). Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 20:03 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,338 | $216.67 | $289,904.46 |
DisclosureSEC source: 0001209191-21-028984 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,333 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $216.67 (range $216.19 to $217.18). Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 20:03 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 2,346 | $215.58 | $505,750.68 |
DisclosureSEC source: 0001209191-21-028984 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,671 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $215.58 (range $215.09 to $216.07). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 20:03 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionCommon Stock | 3,884 | $86.52 | $336,043.68 |
DisclosureSEC source: 0001209191-21-028984 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:03 UTC |
MCKENZIE DIANADirector
|
GrantDeferred Stock Units · Derivative | 124.904 | $220.17 | $27,500.11 |
DisclosureSEC source: 0001209191-21-026940 · doc4.xml · derivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384.469 Underlying: Common Stock · 124.904 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:06 UTC |
SACHS BRUCE IDirector
|
GrantDeferred Stock Units · Derivative | 198.711 | $220.17 | $43,750.20 |
DisclosureSEC source: 0001209191-21-026943 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,021.346 Underlying: Common Stock · 198.711 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:04 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 389 | $214.99 | $83,631.11 |
DisclosureSEC source: 0001209191-21-025841 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,834 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $214.99 (range $214.76 to $215.20). Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:04 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 1,297 | $213.89 | $277,415.33 |
DisclosureSEC source: 0001209191-21-025841 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,223 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $213.89 (range $213.40 to $214.25). F3 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:02 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 1,344 | $214.16 | $287,831.04 |
DisclosureSEC source: 0001209191-21-025105 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,520 Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 256 | $212.28 | $54,343.68 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 6 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,253 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $212.28 (range $212.08 to $212.45). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 1,460 | $211.67 | $309,038.20 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 5 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,509 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $211.67 (range $211.08 to $212.07). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 844 | $210.64 | $177,780.16 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 4 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,969 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $210.64 (range $210.00 to $210.97). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 111 | $209.37 | $23,240.07 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 3 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,813 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $209.37 (range $208.98 to $209.64). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 1,119 | $208.39 | $233,188.41 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 2 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,924 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $208.39 (range $207.93 to $208.67). Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:10 UTC |
Liu JoySVP, General Counsel
|
SaleCommon Stock | 1,351 | $207.57 | $280,427.07 |
DisclosureSEC source: 0001209191-21-018528 · doc4.xml · nonDerivative · entry 1 Liu Joy · CIK 0001847529 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,043 F1 · kind: Transaction made pursuant to Ms. Liu's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $207.57 (range $206.93 to $207.92). F3 · price: Ms. Liu undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:07 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
SaleCommon Stock | 231 | $213.12 | $49,230.72 |
DisclosureSEC source: 0001209191-21-015849 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,884 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27). Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:07 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
SaleCommon Stock | 915 | $212.51 | $194,446.65 |
DisclosureSEC source: 0001209191-21-015849 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,115 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85). Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:07 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
SaleCommon Stock | 610 | $211.45 | $128,984.50 |
DisclosureSEC source: 0001209191-21-015849 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,030 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95). Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:07 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
SaleCommon Stock | 1,026 | $210.13 | $215,593.38 |
DisclosureSEC source: 0001209191-21-015849 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,640 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.